Search
Cryptomeria japonica bark
go.drugbank.com/drugs/DB16633InvestigationalMixtures: Dr. Forest Hand Sanitizer, Dr. Forest Hand SanitizerPerindopril
go.drugbank.com/drugs/DB00790ApprovedInvestigationalATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). … Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications.
Mixtures: PERINDO IN 1A PHA4/1.25MG, PERINDO IN 1A PHA4/1.25MGProducts: PERINDOPRIL ERB 1A PH 4MG, PERINDOPRIL MYLAN GENERICSCiclopirox
go.drugbank.com/drugs/DB01188ApprovedInvestigationalCiclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses.
Categories: Decreased DNA ReplicationRavulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigationalRavulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. … [A244465] Ravulizumab was first approved by the FDA on December 21, 2018, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults.
Ancrod
go.drugbank.com/drugs/DB05099ApprovedWithdrawnFDA granted a 'fast-track status' for investigation of ancrod use in patients suffering from acute ischemic stroke, a life threatening condition caused by the blockage of blood vessels supplying blood … Ancrod, marketed as Viprinex, is a defibrinogenating agent derived from Malayan pit viper venom. The defribrinogenation of blood results in an anticoagulant effect.
Categories: Venombin AElacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigational[L44918,L44948] It received a similar approval in the EU in September 2023. … Elacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist.
Tucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalIt was developed by Seattle Genetics and approved by the FDA on April 17, 2020. … Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer.
Somapacitan
go.drugbank.com/drugs/DB15093ApprovedInvestigational[A219146] Somapacitan was granted FDA approval on 28 August 2020.[L15666] … Somapacitan, also known as NNC0195-0092,[A219136] is a growth hormone analog indicated to treat adults with growth hormone deficiency.
Zanidatamab
go.drugbank.com/drugs/DB15471ApprovedInvestigationalZanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2). … [A264718] In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.[L51908,L51903]
Glucagon
go.drugbank.com/drugs/DB00040ApprovedInvestigationalGlucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia. … [L7640,L7643] Glucagon was granted FDA approval on 14 November 1960.[L7631]
Synonyms: Glucagon (recombinant dna origin)